Sheikhi Maryam, Rostami Mehrdad, Ferns Gordon, Ayatollahi Hossein, Siyadat Payam, Ayatollahi Yasamin, Khoshnegah Zahra
Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Departments of Hematology and Blood Banking, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran.
Caspian J Intern Med. 2024 Spring;15(2):202-214. doi: 10.22088/cjim.15.2.202.
Although genetic mutations in additional sex-combs-like 1 (ASXL1) are prevalent in acute myeloid leukemia (AML), their exact impact on the AML prognosis remains uncertain. Hence, the present article was carried out to explore the prognostic importance of ASXL1 mutations in AML.
We thoroughly searched electronic scientific databases to find eligible papers. Twenty-seven studies with an overall number of 8,953 participants were selected for the current systematic review. The hazard ratio (HR) and 95% confidence interval (CI) for overall survival (OS), event-free survival (EFS), and relapse-free survival (RFS) were extracted from all studies with multivariate or univariate analysis. Pooled HRs and p-values were also calculated as a part of our work.
The pooled HR for OS in multivariable analysis indicated that ASXL1 significantly diminished survival in AML patients (pooled HR: 1.67; 95% CI: 1.342-2.091).
ASXL1 mutations may confer a poor prognosis in AML. Hence, they may be regarded as potential prognostic factors. However, more detailed studies with different ASXL1 mutations are suggested to shed light on this issue.
尽管额外性梳样蛋白1（ASXL1）基因的突变在急性髓系白血病（AML）中普遍存在，但其对AML预后的确切影响仍不确定。因此，本文旨在探讨ASXL1突变在AML中的预后重要性。
我们全面检索了电子科学数据库以查找符合条件的论文。本系统评价选取了27项研究，共8953名参与者。从所有进行多变量或单变量分析的研究中提取总生存期（OS）、无事件生存期（EFS）和无复发生存期（RFS）的风险比（HR）及95%置信区间（CI）。作为我们工作的一部分，还计算了合并的HR和p值。
多变量分析中OS的合并HR表明，ASXL1显著降低了AML患者的生存率（合并HR：1.67；95%CI：1.342 - 2.091）。
ASXL1突变可能预示AML预后不良。因此，它们可能被视为潜在的预后因素。然而，建议开展关于不同ASXL1突变的更详细研究以阐明这一问题。
